Can Fish Oil Cause Atrial Fibrillation?

Fish oil supplements can modestly raise the risk of atrial fibrillation, the most common type of irregular heartbeat. A systematic review and meta-analysis of large cardiovascular trials found that people taking marine omega-3 supplements had a roughly 25% higher chance of developing the condition compared with those taking a placebo, and the risk climbed further at higher doses.¹ The relationship is more complicated than that single number suggests, though, because who you are, how much you take, and whether you already have heart disease all seem to change the picture.

What the Major Trials Found

The concern about fish oil and atrial fibrillation didn’t emerge from a single alarming study. It built up across several large randomized trials originally designed to test whether omega-3 supplements prevent heart attacks and strokes. In those trials, atrial fibrillation was tracked as a secondary outcome or adverse event, and the signal kept showing up.

The REDUCE-IT trial tested icosapent ethyl, a highly purified prescription form of the omega-3 fatty acid EPA, at a dose of 4 grams per day in people with elevated triglycerides. The drug succeeded in its main goal of reducing cardiovascular events, but a higher share of patients in the treatment group were hospitalized for atrial fibrillation or flutter compared with placebo (about 3.1% versus 2.1%).² That gap was statistically significant and put the AF question squarely on cardiologists’ radar.

The VITAL trial, by contrast, tested a standard-dose combination of EPA and DHA (about 840 mg per day of combined omega-3s) in a general healthy population. After more than five years of follow-up, the difference in AF was small and not statistically significant: roughly 3.7% of the fish oil group developed AF versus 3.4% of the placebo group.³ On its own, that trial could easily be read as reassuring. But when pooled with the other trials, a pattern emerges.

Dose Is the Key Variable

When researchers pooled the results of multiple trials, the overall risk of AF was about 25% higher with omega-3 supplements. But the dose mattered enormously. Trials testing doses above 1 gram per day of EPA and DHA saw a much larger increase in AF risk (roughly 49% higher) than trials using 1 gram or less per day (about 12% higher).¹ A meta-regression in that same analysis found that for every additional gram of omega-3s per day, the hazard of developing AF ticked up by about 11%.

This dose gradient is important for context. Most over-the-counter fish oil capsules contain somewhere between 250 mg and 1,000 mg of combined EPA and DHA per serving. So a person taking one standard capsule a day is in the lower-dose range where the signal is weaker, though still present. The higher-dose prescription formulations, like icosapent ethyl at 4 grams per day, live in the zone where the risk is more convincing. If you’re taking multiple capsules per day to hit higher doses on your own, the distinction blurs.

The Paradox of Blood Levels Versus Supplement Use

Here is where the story gets genuinely puzzling. While supplement trials consistently show a small uptick in AF, studies that measure omega-3 levels in the blood tell a different story. A large analysis using UK Biobank data, following participants for a median of nearly 13 years, found that people with higher blood levels of omega-3 fatty acids actually had a lower risk of developing AF. Those in the top fifth of serum omega-3 levels had about a 14% lower risk of AF compared with those in the bottom fifth.⁴

That finding held for DHA and for other omega-3 subtypes as well, and the relationship looked linear: the more omega-3 in the blood, the lower the AF risk. The researchers also looked specifically at fish oil supplement users versus non-users and found that higher omega-3 blood levels were linked to lower AF risk in both groups, but the relationship was actually stronger in people who did not take supplements.

How can supplements raise risk while higher blood levels lower it? One possibility is that blood omega-3 levels largely reflect long-term dietary patterns, such as eating fish regularly, while supplement use involves a concentrated bolus of fatty acids delivered in a way the body handles differently. Another possibility is confounding: people who eat a lot of fish tend to have other healthy habits too, so the biomarker may partly be a marker of overall lifestyle. Researchers have not fully resolved this contradiction, and it remains one of the more interesting loose ends in cardiovascular nutrition research.

How Fish Oil Might Trigger Irregular Rhythm

The biological picture is not simple either. EPA and DHA are not pharmacologically inert molecules that just float around in the bloodstream. They get incorporated into cell membranes, alter how ion channels in the heart behave, and influence electrical signaling across the atrial muscle. A review in Circulation noted that omega-3 fatty acids and their metabolites affect sodium, potassium, and calcium currents in heart cells, change membrane structure and fluidity, and influence inflammation and gene expression.⁵ Some of those effects are protective against certain arrhythmias, while others could promote the electrical disorganization that defines atrial fibrillation.

One proposed pathway involves the vagus nerve, which regulates heart rate and has significant input to the atria. Omega-3 fatty acids can enhance vagal tone, which generally slows the heart. That sounds healthy, and in many contexts it is. But research has suggested that vagally-driven slowing of the heart rate can create uneven recovery times across different patches of atrial muscle. When some areas are still refractory and others have already recovered, an electrical impulse can loop around in a self-sustaining circuit rather than traveling smoothly across the atrium.⁶ That reentry circuit is one of the classic mechanisms for both atrial flutter and atrial fibrillation. In plain terms, the very effect that makes omega-3s good for the heart in one way (calming it down) can become a liability in another way (creating the conditions for an abnormal rhythm to take hold).

Different Outcomes for People With and Without Heart Disease

Perhaps the most practically useful nuance involves whether the person already has cardiovascular disease. A large UK Biobank cohort study found that in people who started out healthy, regular fish oil supplement use was associated with a roughly 13% higher risk of transitioning from no heart disease to atrial fibrillation.⁷ That aligns with the trial data.

But for people who already had a diagnosis of cardiovascular disease, the same study told a different story. Among those who already had atrial fibrillation, fish oil use was associated with a lower risk of progressing to a heart attack or other major cardiovascular event. Fish oil users with existing AF had about an 8% lower risk of progressing to major adverse events and a 15% lower risk of going on to have a heart attack. Among people with heart failure, fish oil use was associated with a lower risk of death.⁷

This is a cohort study rather than a randomized trial, so it cannot prove cause and effect as cleanly. But the pattern fits a plausible story: omega-3s may slightly increase the chance that AF develops in the first place, particularly in healthy people, while simultaneously providing benefits further downstream in the disease process. That dual nature makes blanket advice about fish oil and AF difficult to give.

Prescription Omega-3s Versus Store-Bought Supplements

It helps to recognize that not all fish oil products are created equally. The prescription formulations tested in trials like REDUCE-IT are pharmaceutical-grade, highly purified, and delivered at precise doses. Over-the-counter fish oil supplements are classified as dietary supplements and are not held to the same regulatory standards. Quality, purity, and actual omega-3 content can vary considerably from label to label.⁸

That inconsistency cuts both ways. On one hand, if the AF risk is genuinely dose-dependent, then a supplement that delivers less omega-3 than its label claims is, paradoxically, less risky for AF. On the other hand, unknown contaminants and oxidation products in lower-quality supplements introduce their own concerns. The prescription versions, while cleaner and better studied, are also the ones tested at the higher doses (typically 2 to 4 grams per day) where the AF signal is strongest. If your doctor has prescribed high-dose omega-3s specifically for triglyceride management, the AF risk is part of what they should be weighing against the cardiovascular benefits.

Who Should Be Most Cautious

The existing evidence does not suggest that everyone taking a daily fish oil capsule is heading toward an irregular heartbeat. The absolute risk increase is small: in the VITAL trial, the difference was less than half a percentage point over five years. But certain groups have more reason to pay attention.

People who already have episodes of atrial fibrillation, or who have had ablation procedures or other treatments for the condition, should discuss fish oil with their cardiologist. The same goes for anyone with known structural heart disease, a history of other arrhythmias, or a resting heart rate that is already quite low. The vagally-mediated mechanism discussed earlier implies that those whose hearts are already prone to slow-rate electrical disorganization may be more susceptible.

Age matters too, simply because atrial fibrillation becomes far more common as people get older. A modest relative risk increase of 12 to 25 percent has a larger absolute effect in an 80-year-old than in a 40-year-old, because the baseline risk is higher. If you are in your 30s or 40s with no heart disease, a standard-dose fish oil capsule is unlikely to be the thing that tips you into AF. If you are 70 with borderline risk factors, the calculus changes.

What Happens When You Stop Taking Fish Oil

There isn’t great data yet on whether the AF risk reverses quickly after stopping fish oil. The trials tracked AF events over the entire supplement-use period, and most did not study what happened in the months after people stopped taking the supplements. Because omega-3 fatty acids get incorporated into cell membranes over weeks to months, it seems likely that any effect on atrial electrical properties wouldn’t vanish overnight. Membrane turnover takes time, so a gradual normalization over weeks to months is a reasonable expectation, though it remains understudied.

If you have developed new-onset atrial fibrillation and you take fish oil, stopping the supplement is a reasonable conversation to have with your doctor. It won’t replace medical treatment for the arrhythmia, but removing a potential contributor makes clinical sense while the underlying condition is being managed.

Eating Fish Versus Taking Capsules

People sometimes ask whether they should worry about eating fish too. The answer, based on the available evidence, is probably not. The biomarker data from the UK Biobank study, where higher blood omega-3 levels (which largely reflect dietary fish intake) were associated with lower AF risk, suggests that the usual amounts of omega-3 obtained from eating salmon, sardines, or mackerel a few times a week do not carry the same concern.⁴ A typical serving of fatty fish provides somewhere around 500 mg to 1,500 mg of omega-3s, but those fats are delivered alongside protein, other fats, and micronutrients, in a matrix the body absorbs and metabolizes differently from a concentrated oil capsule.

Dietary guidelines from cardiac organizations still generally recommend eating fish as part of a heart-healthy diet. The AF concern has not changed that advice. It’s the supplemental, concentrated-dose form of omega-3 that has generated the safety signal.

The Social Media Factor

Fish oil’s AF link has become a point of discussion in online patient communities. Research analyzing atrial fibrillation discussions on social media found that triggers such as diet, supplements, stress, and caffeine are common topics alongside personal treatment experiences and the emotional toll of living with the condition.⁹ These discussions can be valuable for people trying to understand their own symptoms, but they can also amplify anxiety in ways that outpace the actual evidence. A personal anecdote about developing AF after starting fish oil is real to the person who experienced it, but it can’t establish causation on its own. The clinical trial data gives a more reliable picture of the size of the risk, and as covered above, it is a modest increase in relative risk rather than a dramatic one.

It’s worth keeping in mind that atrial fibrillation is extremely common in the general population, especially in middle-aged and older adults. Many people develop it regardless of whether they take fish oil. That means some people will inevitably develop AF right around the time they start a supplement purely by coincidence. The trials help separate coincidence from real risk, and what they show is a small, dose-dependent, real but not alarming increase. If fish oil is on your supplement list and your heart rhythm is a concern, the most useful step is to bring the topic up with your doctor, share how much you’re taking, and make the decision together.